Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)

NCT06355531 is registered in ClinicalTrials.gov with Ferrer Internacional S.A. as lead sponsor.

NCT NCT06355531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06355531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)
Lead sponsor
Ferrer Internacional S.A.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 23, 2024
Completion date
November 30, 2026
Enrollment
241 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

progressive supranuclear palsy